Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SPIRIT EXTENSION: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain

NCT03654274 is registered in ClinicalTrials.gov with Myovant Sciences GmbH as lead sponsor.

NCT NCT03654274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03654274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SPIRIT EXTENSION: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain
Lead sponsor
Myovant Sciences GmbH
Phase
Phase 3
Overall status
Completed
Start date
May 22, 2018
Completion date
January 31, 2023
Enrollment
802 (actual)
Sites
169

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis